Value Investor Small Cap Watchlist (TPET, LSDI, LQR, CNEY, LIPO)

In the world of stock investing, size doesn't always dictate success. While large-cap stocks often steal the spotlight, small-cap companies can offer unique opportunities for astute investors. Join us on a journey of discovery as we reveal the potential wealth that lies beneath the surface of these lesser-known companies.

--

Trio Petroleum Corp. (NYSE American: TPET) - Trio Petroleum Corp, based in Bakersfield, California, is an oil and gas exploration and development company with a significant stake in the 9,267-acre 'South Salinas Project' in Monterey County. They currently hold an 85.75% working interest in this asset. Trio's upcoming activities involve testing and producing the HV-1 well, followed by drilling the HV-2 and HV-4 wells. Notably, Trio already owns two production/discovery wells, HV-3A and BM 2-2, on this property. Recently, the company updated the status of HV-1 well testing at the South Salinas Project. They've begun installing a pumping unit and temporary facilities to assess the Brown Zone. Results will be shared when available. The Brown Zone is distinct from the previously tested Mid-Monterey Clay zone. Swab tests suggest a potential combined daily oil production of about 145 BOPD, with the potential for higher rates when the well is fully operational. The company's stock closed last week at $0.46, and we'll be closely monitoring it for any signs of an upward trend.

--

Lucy Scientific Discovery Inc. (NASDAQ: LSDI) - Lucy Scientific Discovery, active in various psychotropic sectors, possesses a Controlled Drugs and Substances Dealer's License from Health Canada. The company and its subsidiary, LSDI Manufacturing Inc., operate under Canada's Part J of Food and Drug Regulations, enabling them to produce pharmaceutical-grade active pharmaceutical ingredients (APIs) for controlled substances and their precursors. Committed to advancing psychotropic medicine, Lucy Scientific Discovery focuses on innovative therapies to improve global mental health and well-being. Last month, the company announced its acquisition of BlueSky Wellness Inc. and its lineup of wellness brands, marking Lucy's expansion into the global wellness market with a focus on psychotropic products. BlueSky Wellness encompasses various plant-based wellness brands, such as Keoni, Keoni Sport, Blush Wellness, and AMMA Healing, with substantial e-commerce sales. Following the acquisition's completion, the BlueSky team will promote Lucy's MINDFUL brand and a diverse range of psychotropic products through their e-commerce platform. The incorporation of recently acquired IP and brand assets from High Times will help reduce customer acquisition costs, enhance user experiences, and tap into new legal markets. With the stock closing last week at $0.37 and a smaller float, we'll closely monitor it for potential upward movement."

--

LQR House Inc. (NASDAQ: LQR) - LQR House, an innovative e-commerce marketing firm, aims to lead the way in digital marketing and brand development for the alcoholic beverage industry. They are currently in a strategic partnership with Country Wine & Spirits Inc. (CWS), giving them full control over marketing operations on CWSpirits.com, a prominent alcohol e-commerce platform. LQR House's team of experienced professionals specializes in tailoring marketing solutions to meet each client's unique needs. With creative branding and digital expertise, they aspire to be the top choice for brands seeking success in the competitive wine and spirits market. Late last month, the company celebrated a major milestone in partnership with Von Payne Whiskey. Thanks to LQR House's tailored marketing campaign, Von Payne Whiskey secured its first purchase order from retail giant Costco. LQR House CEO Sean Dollinger expressed pride in their ability to create buzzworthy brands and provide opportunities for partners, demonstrating their dedication to driving growth. In addition, the company recently announced a public offering of 28,421,053 shares of common stock at $0.19 per share, aiming to raise around $5.4 million. With the stock closing at $0.1723 over the weekend, we'll closely monitor it for potential consolidation and upward movement.

--

CN Energy Group Inc. (NASDAQ: CNEY) - CN Energy Group is a leader in utilizing patented bioengineering and physiochemical technologies to create top-notch, recyclable activated carbon and renewable energy. They transform abandoned forest and agricultural waste into valuable resources, offering substantial financial, economic, environmental, and ecological advantages. Their products and services find extensive application among food and beverage producers, industrial and pharmaceutical manufacturers, and environmental protection firms. Last month, the company's subsidiary, Hangzhou Fulaisen Science and Technology Co., Ltd., secured a substantial order for activated carbon worth RMB 12 million (approximately US $1.64 million). Hangzhou Forasen Technology Co., Ltd. was chosen as the preferred supplier. Ms. Xinyang Wang, CNEY's Board Chairwoman, expressed gratitude for the client's trust and assured timely order fulfillment, high-quality activated carbon, and exceptional after-sales service. The company's stock closed at $0.1077 last week, and with more active management, it has the potential to rebound from its current low.

--

Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) - Lipella, a clinical-stage biotech firm, specializes in reformulating active agents from generic drugs for novel applications. They target diseases with high unmet medical needs, where no approved therapies are available. The company went public in December 2022. Last month, the company announced the publication of successful Phase 2a clinical trial results in the Journal of Urology and Nephrology. Lipella's CEO, Jonathan Kaufman, emphasized the significance of this milestone, highlighting LP-10's potential as a pioneering treatment for hemorrhagic cystitis in cancer survivors. Dr. Michael Chancellor, Lipella's Chief Medical Officer, noted that LP-10 has received Orphan Disease Designation from the FDA and plans for a Phase 2b clinical trial starting in January 2024. The company's stock closed at $0.92 last week, and given its smaller float, there's potential for a rebound, so we'll monitor it closely for consolidation in this range.

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTime Penny is not a fiduciary by virtue of any person's use of or access to this content.